- Home
- NRSN vs CRIS Comparison
NRSN vs CRIS Comparison
Compare NRSN & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRSN
- CRIS
- Stock Information
- Founded
- NRSN 2017
- CRIS 2000
- Country
- NRSN Israel
- CRIS United States
- Employees
- NRSN N/A
- CRIS N/A
- Industry
- NRSN Biotechnology: Pharmaceutical Preparations
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NRSN Health Care
- CRIS Health Care
- Exchange
- NRSN Nasdaq
- CRIS Nasdaq
- Market Cap
- NRSN 26.0M
- CRIS 22.9M
- IPO Year
- NRSN 2021
- CRIS 2000
- Fundamental
- Price
- NRSN $1.18
- CRIS $1.67
- Analyst Decision
- NRSN Buy
- CRIS Strong Buy
- Analyst Count
- NRSN 2
- CRIS 2
- Target Price
- NRSN $14.00
- CRIS $16.50
- AVG Volume (30 Days)
- NRSN 1.4M
- CRIS 76.7K
- Earning Date
- NRSN 09-17-2025
- CRIS 11-13-2025
- Dividend Yield
- NRSN N/A
- CRIS N/A
- EPS Growth
- NRSN N/A
- CRIS N/A
- EPS
- NRSN N/A
- CRIS N/A
- Revenue
- NRSN N/A
- CRIS $11,405,000.00
- Revenue This Year
- NRSN N/A
- CRIS $1.41
- Revenue Next Year
- NRSN N/A
- CRIS $7.46
- P/E Ratio
- NRSN N/A
- CRIS N/A
- Revenue Growth
- NRSN N/A
- CRIS 12.24
- 52 Week Low
- NRSN $0.80
- CRIS $1.02
- 52 Week High
- NRSN $2.60
- CRIS $6.44
- Technical
- Relative Strength Index (RSI)
- NRSN 46.42
- CRIS 45.61
- Support Level
- NRSN $1.14
- CRIS $1.63
- Resistance Level
- NRSN $1.28
- CRIS $1.95
- Average True Range (ATR)
- NRSN 0.15
- CRIS 0.15
- MACD
- NRSN 0.03
- CRIS 0.00
- Stochastic Oscillator
- NRSN 22.33
- CRIS 17.65
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.